Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors
C Chakraborty, SK Ali, H Zhu - Scientific reports, 2014 - nature.com
Some individuals with non-small-cell lung cancer (NSCLC) benefit from therapies targeting
epidermal growth factor receptor (EGFR) and the characterization of a new mechanism of …
epidermal growth factor receptor (EGFR) and the characterization of a new mechanism of …
Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations
B Liu, B Bernard, JH Wu - Proteins: Structure, Function, and …, 2006 - Wiley Online Library
Emergence of resistant mutations in drug targets represents a serious problem in the
targeted chemotherapy. One challenging issue is to understand the atomic‐detailed effect of …
targeted chemotherapy. One challenging issue is to understand the atomic‐detailed effect of …
Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors
Y Cheng, L Ma, Y Liu, J Zhu, Y Xin, X Liu, Y Wang… - Lung cancer, 2020 - Elsevier
Objectives Although the majority of epidermal growth factor receptor (EGFR)-mutant non-
small cell lung cancer (NSCLC) patients respond to EGFR tyrosine kinase inhibitors (TKIs) …
small cell lung cancer (NSCLC) patients respond to EGFR tyrosine kinase inhibitors (TKIs) …
Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures
T Sato, H Watanabe, K Tsuganezawa, H Yuki… - Bioorganic & medicinal …, 2012 - Elsevier
EGFR is a target protein for the treatment of non small cell lung cancer (NSCLC). The
mutations associated with the activation of EGFR kinase activity, such as L858R and G719S …
mutations associated with the activation of EGFR kinase activity, such as L858R and G719S …
Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC
LL Deng, G Gao, HB Deng, F Wang, ZH Wang… - Journal of Cancer …, 2019 - Springer
Purpose To determine the frequency of co-occurring genes in non-small cell lung cancer
(NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and the predictive …
(NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and the predictive …
Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor
UD Bommu, KK Konidala, R Pamanji… - Journal of Receptors …, 2018 - Taylor & Francis
The observable mutated isoforms of epidermal growth factor receptor (EGFR) are important
considerable therapeutic benchmarks in moderating the non-small cell lung cancer …
considerable therapeutic benchmarks in moderating the non-small cell lung cancer …
A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations
H Deng, Q Lei, C Wang, Z Wang, H Chen… - Nature …, 2022 - nature.com
Therapeutic responses of non-small cell lung cancer (NSCLC) to epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are known to be associated with EGFR …
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are known to be associated with EGFR …
Treatment strategies for non-small cell lung cancer harboring common and uncommon EGFR mutations: drug sensitivity based on exon classification, and structure …
R Kitadai, Y Okuma - Cancers, 2022 - mdpi.com
Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou… - BMC medicine, 2023 - Springer
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer
J Ning, Q Wu, Z Liu, J Wang, X Lin - Journal of Receptors and …, 2016 - Taylor & Francis
Human epidermal growth factor receptor (EGFR) has become a well-established target for
the treatment of non-small cell lung cancer (NSCLC). However, a large number of in-frame …
the treatment of non-small cell lung cancer (NSCLC). However, a large number of in-frame …